Moloxin (Moxifloxacin)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA supercoiling, replication, and transcription. By blocking these targets, the drug prevents bacterial DNA synthesis, leading to rapid bacterial cell death and eradication of the infection.

The dose of Moloxin is determined by the prescribing clinician based on the specific infection, its severity, the patient’s weight, renal and hepatic function, and any relevant comorbidities. Dosage regimens are individualized and should follow local clinical guidelines.

Safety of Moloxin in pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare professional.

To order Moloxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain handling if needed) and assist with import documentation.

Moloxin (moxifloxacin) offers a broader spectrum of activity against atypical respiratory pathogens and anaerobes compared with older fluoroquinolones such as ciprofloxacin. It also has enhanced potency against Gram‑positive organisms, but shares the class‑related safety considerations that require careful patient selection.

Moloxin should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect from light, and avoid freezing or shaking the solution. Do not store at room temperature for prolonged periods.

Moloxin is given as an intravenous injection. The solution is typically diluted in compatible IV fluids and infused over a period recommended by the prescriber, often 30‑60 minutes, depending on the clinical situation and patient tolerance.

Serious risks include tendon rupture (especially Achilles), QT interval prolongation leading to cardiac arrhythmias, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be monitored for these events, and therapy discontinued if they occur.

Moloxin is contraindicated in patients with known hypersensitivity to moxifloxacin or other fluoroquinolones. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled QT prolongation, or those receiving concomitant medications that significantly increase the risk of tendon injury or cardiac arrhythmias.